Drug Sales Trends for DAYPRO

Annual Sales Revenues and Units Sold for DAYPRO

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
DAYPRO			2021
DAYPRO			2020
DAYPRO			2019
DAYPRO			2018
DAYPRO			2017
DAYPRO			2016

Market Analysis and Sales Projections for DAYPRO

Introduction to DAYPRO

DAYPRO, also known as oxaprozin, is a non-steroidal anti-inflammatory drug (NSAID) used to manage the signs and symptoms of rheumatoid arthritis and osteoarthritis. It is known for its effectiveness and relatively lower incidence of gastrointestinal side effects compared to other NSAIDs like aspirin.

Market Context of NSAIDs

The global non-opioid pain treatment market, which includes NSAIDs like DAYPRO, is experiencing significant growth. In 2024, the non-opioid pain treatment market was estimated at USD 45.32 billion and is projected to grow at a CAGR of 7.69% from 2025 to 2030[1].

Market Share and Revenue

NSAIDs, the category to which DAYPRO belongs, dominated the non-opioid pain treatment market, accounting for 54.94% of the global revenue in 2024. This dominance is due to the high prescription rate and widespread availability of NSAIDs worldwide[1].

Sales Projections for NSAIDs

Given the broader market trends, here are some key points to consider for DAYPRO's sales projections:

• Global Prescription Drug Revenue: The total prescription drug revenue worldwide is expected to grow significantly, reaching over 1.7 trillion USD by 2030. This growth includes an increase in sales of NSAIDs and other non-opioid pain treatments[3].
• NSAID Market Growth: The high demand for NSAIDs, driven by their effectiveness and safety profile compared to opioids, suggests a continued strong market presence. With over 70 million prescriptions issued annually in the U.S. alone, NSAIDs are a cornerstone in pain management[1].

DAYPRO Specifics

• Clinical Efficacy: DAYPRO has been evaluated in clinical trials for managing rheumatoid arthritis and osteoarthritis. It has been found to be comparable to or more effective than other NSAIDs like aspirin and piroxicam, with fewer gastrointestinal side effects[4].
• Dosage and Administration: DAYPRO is typically administered in once-daily or divided doses, with a long half-life that allows for sustained therapeutic effects. This dosing regimen can contribute to patient compliance and satisfaction[4].

Competitive Landscape

The market for NSAIDs is competitive, with several drugs available. However, DAYPRO's unique pharmacokinetic profile and clinical efficacy make it a viable option for patients and healthcare providers.

Sales Projections

While specific sales projections for DAYPRO are not provided in the available data, we can infer potential growth based on the broader NSAID market trends:

• Market Growth Rate: Given the 7.69% CAGR projected for the non-opioid pain treatment market, it is reasonable to expect that DAYPRO, as a part of this market, could experience similar or slightly lower growth rates.
• Prescription Trends: The high prescription rate of NSAIDs, including DAYPRO, suggests that as the market grows, DAYPRO's sales are likely to increase as well.

Challenges and Opportunities

• Side Effects and Safety: While DAYPRO has a favorable safety profile compared to some other NSAIDs, it still carries risks such as gastrointestinal side effects. Managing these risks through proper dosing and patient monitoring is crucial.
• Competition: The NSAID market is highly competitive, with many drugs available. Differentiating DAYPRO through its unique benefits and marketing strategies will be essential.
• Regulatory Environment: Changes in regulatory policies or guidelines for pain management could impact the sales of DAYPRO. For instance, increased scrutiny on NSAID use could affect prescriptions.

Key Takeaways

• Market Growth: The non-opioid pain treatment market, including NSAIDs like DAYPRO, is expected to grow significantly.
• Clinical Efficacy: DAYPRO has been shown to be effective in managing rheumatoid arthritis and osteoarthritis with a favorable safety profile.
• Sales Projections: While specific projections are not available, DAYPRO is likely to benefit from the overall growth in the NSAID market.
• Competitive Landscape: DAYPRO must differentiate itself in a competitive market through its unique benefits and marketing strategies.

FAQs

Q: What is DAYPRO used for? A: DAYPRO (oxaprozin) is used to manage the signs and symptoms of rheumatoid arthritis and osteoarthritis.

Q: How does DAYPRO compare to other NSAIDs? A: DAYPRO has been found to be comparable to or more effective than other NSAIDs like aspirin and piroxicam, with fewer gastrointestinal side effects.

Q: What is the projected growth rate for the non-opioid pain treatment market? A: The non-opioid pain treatment market is projected to grow at a CAGR of 7.69% from 2025 to 2030.

Q: How widespread is the use of NSAIDs? A: Over 70 million prescriptions for NSAIDs are issued annually in the U.S., and Americans consume over 30 billion doses of NSAIDs each year.

Q: What are the potential challenges for DAYPRO in the market? A: DAYPRO faces challenges such as competition from other NSAIDs, potential side effects, and changes in regulatory policies.

Sources

1. Grand View Research: Non-opioid Pain Treatment Market | Industry Report, 2030
2. Neuren Pharmaceuticals: DAYBUE™ Q1 2024 net sales US$75.9 million, full-year guidance US$370-420 million
3. Statista: Total prescription drug revenue global projection 2022-2030
4. FDA: DAYPRO (oxaprozin) 600mg Caplets - accessdata.fda.gov
5. FirstWord Pharma: Acadia expands ownership of Rett syndrome drug